Clinical study to examine the effectiveness of Juzentaihoto in postoperative recovery for colorectal cancer patients - A research investigating the role of cell-mediated immunity in recovery
Ontology highlight
ABSTRACT: Interventions: Juzentaihoto is administered orally 7.5g/day in 2-3 dosages, before or between meals Total duration of test: 24 weeks starting from one week after surgery
Juzentaihoto is not administered.
Primary outcome(s): 1.ECOG’s Performance Status (ECOG=Eastern Cooperative Oncology Group) 2.Weight 3.QOL-ACD (The QOL Questionnaire for Cancer Patients Treated with Anticancer Drugs) 4.Hematological test (RBC, Hb, Ht, WBC, differential leukocyte count, PLT) 5.Serum albumin 6.Cell-mediated immunity (HLA-DR/CD3, CD11b/CD8, NK-cell activity) 7.Blood cytokine (IL-6, IL-10, IL-12, IL-18, TGF-beta, IFN-gamma) 8.Carcinoembryonic antigen (CEA) 9.Recurrence of cancer 10.Metastasis of cancer 11.Duration of anticancer drug therapy
Study Design: Parallel Randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2616728 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA